Short answer
USANA HEALTH SCIENCES INC (USNA) filed its Q3 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jul 4, 2026. Quarterly revenue was $223M (down 5.3% year over year) with net income of −$21M.
Q3 2026 key financials · XBRL
- Revenue
- $223M
- −5.3% YoY · −10.8% QoQ
- Net income
- −$21M
- −321.5% YoY · −384.5% QoQ
- Operating margin
- -9.0%
- Gross margin
- 78.3%
- EPS (diluted)
- −$1.16
- −323.1% YoY · −382.9% QoQ
Source: XBRL data from the USANA HEALTH SCIENCES INC (USNA) Q3 2026 10-Q on SEC EDGAR. USD.
USANA HEALTH SCIENCES INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $223.3M, down 5.3% YoY from $235.8M
- Consolidated gross margin 78.3% vs 78.7% YoY; operating margin (9.0%) vs 7.1%
- Best segment Rise revenue $3.4M, up 40.3%; worst Hiya revenue $28.3M, down 16.7%
- Hiya goodwill impairment charge $29.1M; net loss $21.4M vs $9.7M net earnings
- Customer and digital marketing headwinds: Core active Customers down 8.1%; Hiya subscribers 166,000 vs 200,400
Risk Factors
- No material changes to risk factors identified in the 2025 Form 10-K
- Share-repurchase authorization $34.0 million as of July 4, 2026
- No share purchases under the repurchase plan during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other USANA HEALTH SCIENCES INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.